Global Liver Institute President and CEO Donna Cryer joins Roger Green to discuss why recent EASL guidelines around use of non-invasive tests (NITs) in Fatty Liver diagnosis and disease tracking is such an important step for patients and treaters alike.
Fatty Liver Foundation President Wayne Eskridge joins Louise Campbell and Roger Green to discuss why he is so enthusiastic about the FDA’s recent approval of the ELF test as a prognostic test for cirrhosis.
NASH kNOWledge President Anthony Villiotti joins Louise Campbell and Roger Green to highlight two recent publications about NAFLD/NASH prevalence (underestimated!) and patient awareness (miniscule!) and what that portends for the future.
Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This conversation focuses on current and potential impact of the Delta and future variants on clinical trial performance.
Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This discussion focuses on the process of moving immunocompromised and transplant patients to the front of the booster dose queue.
Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation constitutes a call to action for the Surfers and our listeners.
Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on how to drive a broader change in perspective.
Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on the unique challenges in treating NASH cirrhosis.
Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis, which evolves into a discussion about how to drive NITs forward.
Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGFs) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation detours into health policy and screen fail rates before returning to consider the 2-5 year implications of FGF drug therapies.
